Literature DB >> 33525518

The Role of Non-Canonical Hsp70s (Hsp110/Grp170) in Cancer.

Graham Chakafana1, Addmore Shonhai1.   

Abstract

Although cancers account for over 16% of all global deaths annually, at present, no reliable therapies exist for most types of the disease. As protein folding facilitators, heat shock proteins (Hsps) play an important role in cancer development. Not surprisingly, Hsps are among leading anticancer drug targets. Generally, Hsp70s are divided into two main subtypes: canonical Hsp70 (Escherichia coli Hsp70/DnaK homologues) and the non-canonical (Hsp110 and Grp170) members. These two main Hsp70 groups are delineated from each other by distinct structural and functional specifications. Non-canonical Hsp70s are considered as holdase chaperones, while canonical Hsp70s are refoldases. This unique characteristic feature is mirrored by the distinct structural features of these two groups of chaperones. Hsp110/Grp170 members are larger as they possess an extended acidic insertion in their substrate binding domains. While the role of canonical Hsp70s in cancer has received a fair share of attention, the roles of non-canonical Hsp70s in cancer development has received less attention in comparison. In the current review, we discuss the structure-function features of non-canonical Hsp70s members and how these features impact their role in cancer development. We further mapped out their interactome and discussed the prospects of targeting these proteins in cancer therapy.

Entities:  

Keywords:  Grp170; Hsp110; cancer; chaperone; non-canonical Hsp70

Year:  2021        PMID: 33525518      PMCID: PMC7911927          DOI: 10.3390/cells10020254

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  146 in total

Review 1.  The nuclear pore complex and nuclear transport.

Authors:  Susan R Wente; Michael P Rout
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-07-14       Impact factor: 10.005

2.  Structural basis for the cooperation of Hsp70 and Hsp110 chaperones in protein folding.

Authors:  Sigrun Polier; Zdravko Dragovic; F Ulrich Hartl; Andreas Bracher
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

3.  Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy.

Authors:  Gustavo J Gozzi; Daniel Gonzalez; Christophe Boudesco; Alexandre M M Dias; Guillaume Gotthard; Burhan Uyanik; Lucile Dondaine; Guillaume Marcion; François Hermetet; Camille Denis; Laurianne Hardy; Peggy Suzanne; Romain Douhard; Gaetan Jego; Laurence Dubrez; Oleg N Demidov; Fabrice Neiers; Loïc Briand; Jana Sopková-de Oliveira Santos; Anne-Sophie Voisin-Chiret; Carmen Garrido
Journal:  Cell Death Differ       Date:  2019-05-08       Impact factor: 15.828

4.  Immunohistochemical detection of the 150-kDa oxygen-regulated protein in bladder cancer.

Authors:  H Asahi; K Koshida; O Hori; S Ogawa; M Namiki
Journal:  BJU Int       Date:  2002-09       Impact factor: 5.588

5.  Heat shock proteins create a signature to predict the clinical outcome in breast cancer.

Authors:  Marta Klimczak; Przemyslaw Biecek; Alicja Zylicz; Maciej Zylicz
Journal:  Sci Rep       Date:  2019-05-17       Impact factor: 4.379

Review 6.  Comparative structure-function features of Hsp70s of Plasmodium falciparum and human origins.

Authors:  Graham Chakafana; Tawanda Zininga; Addmore Shonhai
Journal:  Biophys Rev       Date:  2019-07-06

Review 7.  Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy.

Authors:  Chul Won Yun; Hyung Joo Kim; Ji Ho Lim; Sang Hun Lee
Journal:  Cells       Date:  2019-12-24       Impact factor: 6.600

8.  Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.

Authors:  X Wu; A Wanders; P Wardega; B Tinge; L Gedda; S Bergstrom; L Sooman; J Gullbo; M Bergqvist; P Hesselius; J Lennartsson; S Ekman
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

9.  Assessment of the evolution of cancer treatment therapies.

Authors:  Manuel Arruebo; Nuria Vilaboa; Berta Sáez-Gutierrez; Julio Lambea; Alejandro Tres; Mónica Valladares; Africa González-Fernández
Journal:  Cancers (Basel)       Date:  2011-08-12       Impact factor: 6.639

Review 10.  Role of STAT3 signaling pathway in breast cancer.

Authors:  Jia-Hui Ma; Li Qin; Xia Li
Journal:  Cell Commun Signal       Date:  2020-02-28       Impact factor: 5.712

View more
  2 in total

Review 1.  Host cell stress response as a predictor of COVID-19 infectivity and disease progression.

Authors:  Celine Caillet; Melissa Louise Stofberg; Victor Muleya; Addmore Shonhai; Tawanda Zininga
Journal:  Front Mol Biosci       Date:  2022-08-11

2.  Species-Specific Endotoxin Stimulus Determines Toll-Like Receptor 4- and Caspase 11-Mediated Pathway Activation Characteristics.

Authors:  Orna Ernst; Mohd M Khan; Benjamin L Oyler; Sung Hwan Yoon; Jing Sun; Fang-Yu Lin; Nathan P Manes; Alexander D MacKerell; Iain D C Fraser; Robert K Ernst; David R Goodlett; Aleksandra Nita-Lazar
Journal:  mSystems       Date:  2021-08-03       Impact factor: 6.496

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.